These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38898657)

  • 1. A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
    Joshi S; Spargo A; Hoyt M; Panni T; Viktrup L; Kim G; Hasan A; Liu YY; Zakharyan A
    Headache; 2024; 64(7):796-809. PubMed ID: 38898657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
    Varnado OJ; Vu M; Buysman EK; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    Curr Med Res Opin; 2024 Apr; 40(4):635-646. PubMed ID: 38334320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States.
    Varnado OJ; Vu M; Buysman E; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    J Manag Care Spec Pharm; 2024 Aug; 30(8):792-804. PubMed ID: 39088336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.
    Ford JH; Ye W; Nichols RM; Foster SA; Nelson DR
    J Med Econ; 2019 Sep; 22(9):849-858. PubMed ID: 30977712
    [No Abstract]   [Full Text] [Related]  

  • 8. Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States.
    Woolley JM; Bonafede MM; Maiese BA; Lenz RA
    Headache; 2017 Oct; 57(9):1399-1408. PubMed ID: 28842990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database.
    Ford JH; Schroeder K; Buse DC; Joshi S; Gelwicks S; Foster SA; Aurora SK
    Curr Med Res Opin; 2020 Jan; 36(1):51-61. PubMed ID: 31422701
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study.
    Irimia P; García-Azorín D; Núñez M; Díaz-Cerezo S; de Polavieja PG; Panni T; Sicras-Navarro A; Sicras-Mainar A; Ciudad A
    J Headache Pain; 2022 Jul; 23(1):78. PubMed ID: 35794535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
    Tepper SJ; Schwedt TJ; Vo P; Thompson J; Joshi P; Abdrabboh A; Ferraris M; Tiwari S
    Headache; 2023; 63(10):1423-1436. PubMed ID: 37655551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Foster SA; Hoyt M; Ye W; Mason O; Ford JH
    Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States.
    Varnado OJ; Gulati T; Wheeler A; Hoyt M
    Patient Prefer Adherence; 2023; 17():3449-3459. PubMed ID: 38143945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
    Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States.
    Krasenbaum LJ; Pedarla VL; Thompson SF; Tangirala K; Cohen JM; Driessen MT
    J Headache Pain; 2022 May; 23(1):54. PubMed ID: 35508970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 20. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.
    Silberstein SD; Feliu AL; Rupnow MF; Blount AC; Boccuzzi SJ
    Headache; 2007 Apr; 47(4):500-10. PubMed ID: 17445099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.